Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000229111 | SCV000288342 | likely benign | Neuroblastoma, susceptibility to, 3 | 2025-02-02 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000229111 | SCV000895459 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002257559 | SCV002528459 | benign | Hereditary cancer-predisposing syndrome | 2021-12-09 | criteria provided, single submitter | curation | |
Gene |
RCV002307461 | SCV002601367 | uncertain significance | not provided | 2025-01-22 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002257559 | SCV002607985 | likely benign | Hereditary cancer-predisposing syndrome | 2022-01-18 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |